AN2 Therapeutics Advances Oral Drug Candidate AN2-502998 to Phase 2 Trial for Chagas Disease

AN2 Therapeutics announced on Thursday that it has gathered data supporting the advancement of its oral drug candidate, AN2-502998, into a Phase 2 clinical trial for the treatment of chronic Chagas disease. The company confirmed that the findings from its recent research provide the necessary evidence to proceed with the next stage of clinical development for the investigational therapy.

The data stems from recent evaluations designed to assess the drug’s potential as a treatment for the parasitic infection. By meeting these specific developmental milestones, the company now prepares to initiate a Phase 2 study to further evaluate the efficacy and safety profile of the oral medication in patients. AN2 Therapeutics intends to use these results to guide the design and implementation of the upcoming trial, marking a transition from preliminary research to mid-stage human testing.

Newsflash | Powered by GeneOnline AI

Source: GO-AI-ne1

For any suggestion and feedback, please contact us.

Date: June 4, 2026

Author

GOAI